Investigational drug · Phase 2
AZD4144
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sepsis, Acute Kidney Injury.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "AZD4144"
First trial start
2026
Feb 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD4144", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Sepsis
- Acute Kidney Injury
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD4144" as an intervention, largest first.
- A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07215702 · 124 participants (planned) · Start Feb 10, 2026 · Primary completion Feb 11, 2027
Drug: AZD4144; Placebo · For: Sepsis; Acute Kidney Injury
Sites: Phoenix, Arizona; Newport Beach, California; Kansas City, Kansas · 74 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06122714 · 95 participants · Start Nov 7, 2023 · Primary completion Dec 4, 2024
Drug: AZD4144 Part A; AZD4144 Part B and 2 more · For: Healthy Participants
Sites: Glendale, California; Brooklyn, Maryland
AstraZenecaAstraZeneca (AZN)
NCT06491550 · 91 participants · Start Jul 15, 2024 · Primary completion Jun 11, 2025
Drug: AZD4144- Part A; Placebo- Part A and 4 more · For: Healthy Participants
Sites: Glendale, California; Brooklyn, Maryland
AstraZenecaAstraZeneca (AZN)
NCT06693765 · 41 participants · Start Nov 18, 2024 · Primary completion Apr 23, 2025
Drug: AZD4144 · For: Renal Impairment; End-stage Kidney Disease; Healthy Participants
Sites: Sofia, Bulgaria; Bucharest, Romania
AstraZenecaAstraZeneca (AZN)
NCT06948006 · 32 participants · Start Apr 23, 2025 · Primary completion Jun 27, 2025
Drug: AZD4144; Omeprazole · For: Healthy Participants
Sites: Harrow, United Kingdom
- Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy ParticipantsCompleted
AstraZenecaAstraZeneca (AZN)
NCT07685600 · 32 participants · Start Jul 30, 2026 · Primary completion Oct 22, 2026
Drug: AZD4144; AZD4144 and 1 more · For: Healthy
Sites: Harrow, United Kingdom
- A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144Not yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07783308 · 30 participants (planned) · Start Aug 24, 2026 · Primary completion May 28, 2027
Drug: AZD4144 · For: Hepatic Impairment
Sites: Mesa, Arizona; Miami Lakes, Florida; Orlando, Florida · 4 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06675175 · 29 participants · Start Dec 9, 2024 · Primary completion Oct 27, 2025
Drug: AZD4144 · For: Chronic Kidney Disease; Atherosclerotic Cardiovascular Disease
Sites: Glendale, California; Daytona Beach, Florida; Jacksonville, Florida · 15 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06942923 · 28 participants · Start Apr 22, 2025 · Primary completion Sep 29, 2025
Drug: AZD4144; Placebo · For: Healthy Participants
Sites: Berlin, Germany
AstraZenecaAstraZeneca (AZN)
NCT07518459 · 16 participants · Start Feb 11, 2026 · Primary completion May 26, 2026
Drug: [14C]AZD4144 Solution for Infusion; [14C]AZD4144 Oral Solution · For: Healthy Participants
Sites: Ruddington, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- The NLRP3 inflammasome in chronic kidney disease progression: systematic review of preclinical models reveals a critical gap in pyroptosis research and therapeutic translation.
More SA, Patil A, Joshi M, et al. · Mol Biol Rep 2026
- Discovery of AZD4144, a Selective and Potent NLRP3 Inhibitor for the Treatment of Inflammatory Diseases.
Johansson A, Sugama H, Larsson N, et al. · J Med Chem 2025
Also in development for Sepsis
- YD0743Phase 21 trial
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Sepsis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.